Medpace Holdings Management
Management Kriterienprüfungen 3/4
Medpace Holdings CEO ist August Troendle , ernannt in Jul 1992, hat eine Amtszeit von 33.83 Jahren. Die jährliche Gesamtvergütung beträgt $11.44M , bestehend aus 8.2% Gehalt und 91.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 18.83% der Aktien des Unternehmens, im Wert von $2.25B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 7.3 Jahre bzw. 7.8 Jahre.
Wichtige Informationen
August Troendle
Geschäftsführender
US$11.4m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 8.19% |
| Amtszeit als Geschäftsführer | 33.8yrs |
| Eigentum des Geschäftsführers | 18.8% |
| Durchschnittliche Amtszeit des Managements | 7.3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 7.8yrs |
Jüngste Management Updates
Recent updates
MEDP: Biotech Trial Efficiency And AI Savings Will Support Future Margin Resilience
Medpace Holdings' analyst price target has been reset from about $582 to roughly $495 as analysts factor in updated assumptions for revenue growth, margins and future P/E multiples, while still pointing to company specific strengths highlighted in recent research coverage and upgrades. Analyst Commentary Street research around Medpace has recently centered on recalibrating price targets while still emphasizing company specific strengths.Medpace Holdings, Inc. Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Apr 26
Medpace Holdings: Downgrade To 'Buy' As Revenue Growth Remains, But With Caution Ahead
Apr 24
MEDP: Slower Revenue Assumptions Will Test Rich Multiple And 2026 Execution
Medpace Holdings' analyst-derived fair value has inched up by about $5 to roughly $357, as analysts weigh higher assumed profit margins and a richer future P/E against slower projected revenue growth and a slightly higher discount rate, while incorporating a wave of recent rating upgrades and higher price targets clustered around $419 to $522. Analyst Commentary Recent research on Medpace reflects a mix of upgrades and cautious fine tuning, with several firms lifting ratings while keeping a close eye on valuation, end market trends, and execution risk.
MEDP: Efficient Biotech Contracts And Buybacks Will Support Elevated Market Expectations
Analysts have inched up their blended price target on Medpace Holdings to about $500 per share from roughly $490, citing the company’s efficiency in contract research, ongoing biotech-focused wins, and a series of recent rating upgrades as key reasons for this recalibration. Analyst Commentary Recent research remains broadly constructive on Medpace, with several firms adjusting ratings and price targets as they reassess valuation, execution, and exposure to biotech customers.MEDP: Biotech Trial Efficiency And AI Savings Will Support Future Margin Strength
Analysts have nudged their overall price expectations for Medpace modestly higher, reflected in a slightly lower discount rate of 7.78% and small upward tweaks to revenue growth and profit margin assumptions. These changes are supported by a series of recent rating upgrades and fresh price targets in the $419 to $660 range.MEDP: Efficiency And Biotech Exposure Will Support Margin Strength Going Forward
Analysts have lifted their implied fair value estimate for Medpace Holdings to $582 from $510, citing the company's efficiency as a contract research organization, stronger profit margin assumptions at 17.94%, and a higher future P/E of about 29.35x as key supports for the updated price targets across recent research. Analyst Commentary Recent research coverage has highlighted a generally constructive tone around Medpace, with several bullish analysts pointing to efficiency, exposure to biopharma clients, and margin profile as key parts of the equity story.MEDP: Higher Margins And Buybacks Will Support Rich Market Expectations
Analysts have trimmed their average price target on Medpace Holdings by about $55 to $490.50 as revised models reflect updated revenue growth assumptions, a slightly different discount rate, higher expected profit margins, and a higher future P/E multiple, informed by a mix of recent upgrades and target changes across the Street. Analyst Commentary Recent research has produced a mix of upgrades and target cuts, with Street views clustering around how sustainable Medpace Holdings' growth, margins, and valuation may be after the latest earnings move.Medpace Holdings, Inc. (NASDAQ:MEDP) Just Reported, And Analysts Assigned A US$491 Price Target
Feb 13MEDP: Decelerating Healthcare Utilization Will Test Rich Multiple And 2026 Execution
Analysts have nudged their price target for Medpace Holdings slightly higher, to $660 from $655, citing updated Q4 healthcare utilization survey findings and modest tweaks to growth, margin and future P/E assumptions in their models. Analyst Commentary Recent research around Medpace focuses on how healthcare utilization trends could influence growth expectations, margins and the valuation investors are willing to pay.MEDP: Biotech Recovery And Backlog Strength Will Challenge Rich Market Expectations
Narrative Update: Medpace Holdings Analyst Price Target Shift The updated analyst framework edges fair value for Medpace Holdings slightly higher to about $545.75 from roughly $541.92. This reflects modest tweaks to discount rate, growth, margin and P/E assumptions as analysts respond to a series of recent price target increases across the Street.MEDP: Rich Multiple Will Depend On Unproven 2026 Execution
Analysts raised their fair value estimate for Medpace Holdings from about $305 to roughly $356 per share, citing higher assumed revenue growth, slightly improved profit margins, and a modestly higher future P/E multiple in line with recent Street price target increases. Analyst Commentary Recent Street research on Medpace highlights a mix of optimism on the long term setup and caution around how much upside is already reflected in the current share price.MEDP: Biotech Funding Recovery And Backlog Trends Will Shape Future Prospects
Analysts have nudged their blended fair value estimate for Medpace Holdings slightly higher, to approximately $542 from $539, citing increased confidence in the durability of biotech recovery, a healthier pre-backlog pipeline, and signs that contract research trends have stabilized. Analyst Commentary Street research updates over the last several weeks reflect a generally constructive stance on Medpace, with multiple firms raising price targets while maintaining a range of ratings from Sell to Outperform.MEDP: Biotech Funding Recovery And Book-To-Bill Trends Will Shape Future Outlook
Analysts have nudged their price target on Medpace Holdings modestly higher by about $2 per share to reflect increased confidence in a sustained recovery in biotech funding, healthier book to bill trends, and signs that contract research organization demand has likely stabilized. Analyst Commentary Recent Street research reflects a more constructive stance on Medpace, with several bullish analysts lifting price targets to account for stronger sector fundamentals and improved visibility into the company’s growth trajectory.MEDP: Improving Biotech Pipeline And Book-To-Bill Trends Will Support Recovery Momentum
The analyst price target for Medpace Holdings has increased from $519 to $538. Analysts cite improving Biotech market confidence and stronger forward earnings projections as factors supporting this upward revision.MEDP: Below-Normal Bookings In 2025 Will Pressure Revenue Expansion
Analysts have raised their price target for Medpace Holdings from $456 to approximately $519, citing higher growth estimates and renewed confidence in the CRO sector's recovery. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for Medpace, citing increased confidence in the recovery trajectory of the biotech sector and the broader contract research organization market.Future Sector Demand Shifts Will Influence Risk And Reward Dynamics
Analysts have raised their fair value estimate for Medpace Holdings to $456 from $428 per share. This change reflects updated optimism based on recent price target adjustments and expectations for stabilization in contract research organization demand trends.Tech-enabled Clinical Trials Will Balance Potential Risk And Reward
Analysts have raised Medpace Holdings’ fair value estimate modestly, from $423.64 to $428.00. Industry views reflect improved biotech funding and solid bookings, although some ongoing uncertainty in demand signals remains.Tech-enabled Clinical Trials Will Balance Potential Risk And Reward
As key metrics including the discount rate (7.16%) and net profit margin (16.85%) remained stable, the consensus analyst price target for Medpace Holdings was unchanged at $422.27. What's in the News Medpace completed a repurchase of 1,754,264 shares (5.89% of shares outstanding) for $518.54 million in Q2 2025, bringing the total buyback under its current program to 14.76% of shares outstanding and $1.27 billion since October 2022 (Key Developments).Earnings Not Telling The Story For Medpace Holdings, Inc. (NASDAQ:MEDP) After Shares Rise 34%
Aug 11Medpace Holdings, Inc. Beat Revenue Forecasts By 12%: Here's What Analysts Are Forecasting Next
Jul 24Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?
Jul 01Is Medpace Holdings, Inc. (NASDAQ:MEDP) Trading At A 48% Discount?
Jun 12Investor Optimism Abounds Medpace Holdings, Inc. (NASDAQ:MEDP) But Growth Is Lacking
May 08Medpace: Impressive Revenue Growth, High ROE Values, And High Growth Potential
Feb 06Medpace: Buy The Short-Term Pain For Long-Term Gains
Oct 26Why Medpace Holdings Is A 'Better Mousetrap'
Oct 16
Temporary Setbacks Poised For A Swift Recovery And Strong Future Revenue Growth
Elevated project cancellations pose only a temporary risk, with potential for quick revenue and net new business awards recovery.Medpace: Continued Business Growth With Asymmetrical Payoff Opportunity
Aug 20Medpace: Clear Winner If China Blockade Succeeds
Jun 04Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$460m |
| Dec 31 2025 | US$11m | US$937k | US$451m |
| Sep 30 2025 | n/a | n/a | US$433m |
| Jun 30 2025 | n/a | n/a | US$418m |
| Mar 31 2025 | n/a | n/a | US$416m |
| Dec 31 2024 | US$9m | US$866k | US$404m |
| Sep 30 2024 | n/a | n/a | US$366m |
| Jun 30 2024 | n/a | n/a | US$340m |
| Mar 31 2024 | n/a | n/a | US$312m |
| Dec 31 2023 | US$2m | US$814k | US$283m |
| Sep 30 2023 | n/a | n/a | US$273m |
| Jun 30 2023 | n/a | n/a | US$268m |
| Mar 31 2023 | n/a | n/a | US$257m |
| Dec 31 2022 | US$2m | US$770k | US$245m |
| Sep 30 2022 | n/a | n/a | US$227m |
| Jun 30 2022 | n/a | n/a | US$209m |
| Mar 31 2022 | n/a | n/a | US$199m |
| Dec 31 2021 | US$6m | US$697k | US$181m |
| Sep 30 2021 | n/a | n/a | US$182m |
| Jun 30 2021 | n/a | n/a | US$175m |
| Mar 31 2021 | n/a | n/a | US$159m |
| Dec 31 2020 | US$4m | US$608k | US$145m |
| Sep 30 2020 | n/a | n/a | US$124m |
| Jun 30 2020 | n/a | n/a | US$107m |
| Mar 31 2020 | n/a | n/a | US$110m |
| Dec 31 2019 | US$8m | US$504k | US$100m |
Vergütung im Vergleich zum Markt: AugustDie Gesamtvergütung ($USD11.44M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD14.60M).
Entschädigung vs. Einkommen: AugustDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.
Geschäftsführer
August Troendle (69 yo)
33.8yrs
Amtszeit
US$11,443,766
Vergütung
Dr. August James Troendle, M.D. serves as Chairman of CinRx Pharma, LLC. He has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman & CEO | 33.8yrs | US$11.44m | 18.83% $ 2.2b | |
| President | 4.8yrs | US$2.40m | 0.053% $ 6.3m | |
| CFO & Treasurer | 7.3yrs | US$1.65m | 0.045% $ 5.4m | |
| Executive Vice President of Operations | 9.3yrs | US$2.72m | 0.25% $ 29.4m | |
| Chief Compliance Officer | 13.9yrs | US$2.02m | 0.071% $ 8.5m | |
| Chief Information Officer | 5.3yrs | keine Daten | keine Daten | |
| Associate Director of Investors Relations | no data | keine Daten | keine Daten | |
| Vice President of Business Development & Marketing | no data | keine Daten | keine Daten | |
| Senior Vice President of Biometrics | no data | keine Daten | keine Daten | |
| Senior Vice President of Commercial Operations & Clinical Pharmacology Unit | no data | keine Daten | keine Daten | |
| Chief Medical Officer of Medical Department | 3.3yrs | keine Daten | keine Daten | |
| Senior Vice President of Clinical Monitoring | no data | keine Daten | keine Daten |
7.3yrs
Durchschnittliche Betriebszugehörigkeit
59yo
Durchschnittliches Alter
Erfahrenes Management: Das Managementteam von MEDP ist erfahren und erfahren (durchschnittliche Amtszeit von 7.3 Jahren).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman & CEO | 33.8yrs | US$11.44m | 18.83% $ 2.2b | |
| Lead Independent Director | 7.8yrs | US$264.94k | 0.019% $ 2.3m | |
| Independent Director | 7.8yrs | US$217.39k | 0.036% $ 4.3m | |
| Independent Director | 9.8yrs | US$227.26k | 0.0032% $ 385.2k | |
| Independent Director | 9.8yrs | US$234.76k | 0.11% $ 13.7m | |
| Independent Director | 3.3yrs | US$209.94k | 0% $ 0 | |
| Independent Director | 1.8yrs | US$209.94k | 0% $ 0 |
7.8yrs
Durchschnittliche Betriebszugehörigkeit
65yo
Durchschnittliches Alter
Erfahrener Vorstand: MEDPDie Vorstandsmitglieder gelten als erfahren (7.8 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/04 21:11 |
| Aktienkurs zum Tagesende | 2026/05/01 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Medpace Holdings, Inc. wird von 20 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |